A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Conditions: Moderate Plaque Psoriasis Interventions: Drug: Risankizumab; Drug: Deucravacitinib Sponsors: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials